Plasma antioxidant potential measured by total radical trapping antioxidant parameter in a cohort of multiple sclerosis patients

Abstract Background Oxidative injury has been implicated as a mediator of demyelination, axonal damage, and neurodegeneration in multiple sclerosis (MS). There is a high demand for oxidative injury biomarkers. The aim of the study was to evaluate MS patients’ plasma antioxidant potential using the t...

Full description

Bibliographic Details
Main Authors: Marge Kartau, Joonas Kartau, Marjatta Pohja, Auli Verkkoniemi‐Ahola
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Brain and Behavior
Subjects:
Online Access:https://doi.org/10.1002/brb3.3377
_version_ 1797263391791775744
author Marge Kartau
Joonas Kartau
Marjatta Pohja
Auli Verkkoniemi‐Ahola
author_facet Marge Kartau
Joonas Kartau
Marjatta Pohja
Auli Verkkoniemi‐Ahola
author_sort Marge Kartau
collection DOAJ
description Abstract Background Oxidative injury has been implicated as a mediator of demyelination, axonal damage, and neurodegeneration in multiple sclerosis (MS). There is a high demand for oxidative injury biomarkers. The aim of the study was to evaluate MS patients’ plasma antioxidant potential using the total radical trapping parameter (TRAP) assay and examine its usefulness as an MS disease biomarker. Methods A total number of 112 MS patients underwent an analysis of TRAP. In addition, plasma uric acid (UA) levels were analyzed. The neurological and radiological data were collected from patient records from Helsinki University Hospital during 2012–2013 when first‐line injectables of moderate‐efficacy, natalizumab (NTZ), and fingolimod (FTY) of high efficacy disease modifying therapies and in some cases azathioprine (AZT) were used to treat MS. Results TRAP values were negatively associated with expanded disability status scale (EDSS) score with p‐value .052, β = −28. There was also a negative association in TRAP values between patients with no medication (n = 22, TRAP mean 1255 μmol/L (95% confidence interval [CI] 1136–1374)) and patients who received NTZ, p‐value .020 (n = 19, TRAP mean was 991 μmol/L (95% CI 849–1133) or FTY treatment, p‐value .030 (n = 5, TRAP mean 982 μmol/L (95% CI 55–1909). Due to a small sample size, these results were not significant after applying a false discovery rate correction at a 0.05 significance level but are worth highlighting. Men in the study had higher TRAP values, p‐value = .001 (TRAP mean 1320 ± 293 μmol/L) than women (TRAP mean 1082 ± 288 μmol/L). UA was positively associated with TRAP values, p‐value <.001 and UA levels in men (UA mean 334.5 ± 62.6 μmol/L) were higher compared to women (UA mean 240 ± 55.8 μmol/L), t‐test p‐value <.001. The significant difference in TRAP levels between genders, with men showing higher TRAP values than women, may be attributed to the variation in UA levels. Conclusion Our findings suggest that lower plasma antioxidant potential is linked to more severe disability measured by EDSS scores. Patients treated with NTZ and FTY had reduced antioxidant power, which might be influenced by the active MS disease rather than the treatments themselves. The study reveals a strong positive correlation between UA levels and TRAP, particularly among women. However, men on average had better antioxidant potential than women. Neither the disease type nor the duration influences TRAP levels. While serving as a marker of antioxidant potential, plasma TRAP in MS patients does not reliably reflect overall oxidative stress (OS) and should not be solely used as an indicator of OS.
first_indexed 2024-03-07T23:34:28Z
format Article
id doaj.art-61617609830645f4be54924ed0519763
institution Directory Open Access Journal
issn 2162-3279
language English
last_indexed 2024-04-25T00:12:16Z
publishDate 2024-01-01
publisher Wiley
record_format Article
series Brain and Behavior
spelling doaj.art-61617609830645f4be54924ed05197632024-03-13T10:15:39ZengWileyBrain and Behavior2162-32792024-01-01141n/an/a10.1002/brb3.3377Plasma antioxidant potential measured by total radical trapping antioxidant parameter in a cohort of multiple sclerosis patientsMarge Kartau0Joonas Kartau1Marjatta Pohja2Auli Verkkoniemi‐Ahola3Clinical Neurosciences, Neurology Helsinki University Hospital and Helsinki University Helsinki FinlandDepartment of Mathematics and Statistics University of Helsinki Helsinki FinlandClinical Neurosciences, Neurology Helsinki University Hospital Helsinki FinlandClinical Neurosciences, Neurology Helsinki University Hospital Helsinki FinlandAbstract Background Oxidative injury has been implicated as a mediator of demyelination, axonal damage, and neurodegeneration in multiple sclerosis (MS). There is a high demand for oxidative injury biomarkers. The aim of the study was to evaluate MS patients’ plasma antioxidant potential using the total radical trapping parameter (TRAP) assay and examine its usefulness as an MS disease biomarker. Methods A total number of 112 MS patients underwent an analysis of TRAP. In addition, plasma uric acid (UA) levels were analyzed. The neurological and radiological data were collected from patient records from Helsinki University Hospital during 2012–2013 when first‐line injectables of moderate‐efficacy, natalizumab (NTZ), and fingolimod (FTY) of high efficacy disease modifying therapies and in some cases azathioprine (AZT) were used to treat MS. Results TRAP values were negatively associated with expanded disability status scale (EDSS) score with p‐value .052, β = −28. There was also a negative association in TRAP values between patients with no medication (n = 22, TRAP mean 1255 μmol/L (95% confidence interval [CI] 1136–1374)) and patients who received NTZ, p‐value .020 (n = 19, TRAP mean was 991 μmol/L (95% CI 849–1133) or FTY treatment, p‐value .030 (n = 5, TRAP mean 982 μmol/L (95% CI 55–1909). Due to a small sample size, these results were not significant after applying a false discovery rate correction at a 0.05 significance level but are worth highlighting. Men in the study had higher TRAP values, p‐value = .001 (TRAP mean 1320 ± 293 μmol/L) than women (TRAP mean 1082 ± 288 μmol/L). UA was positively associated with TRAP values, p‐value <.001 and UA levels in men (UA mean 334.5 ± 62.6 μmol/L) were higher compared to women (UA mean 240 ± 55.8 μmol/L), t‐test p‐value <.001. The significant difference in TRAP levels between genders, with men showing higher TRAP values than women, may be attributed to the variation in UA levels. Conclusion Our findings suggest that lower plasma antioxidant potential is linked to more severe disability measured by EDSS scores. Patients treated with NTZ and FTY had reduced antioxidant power, which might be influenced by the active MS disease rather than the treatments themselves. The study reveals a strong positive correlation between UA levels and TRAP, particularly among women. However, men on average had better antioxidant potential than women. Neither the disease type nor the duration influences TRAP levels. While serving as a marker of antioxidant potential, plasma TRAP in MS patients does not reliably reflect overall oxidative stress (OS) and should not be solely used as an indicator of OS.https://doi.org/10.1002/brb3.3377biomarkermultiple sclerosisoxidative stresstotal radical trapping parameter assay
spellingShingle Marge Kartau
Joonas Kartau
Marjatta Pohja
Auli Verkkoniemi‐Ahola
Plasma antioxidant potential measured by total radical trapping antioxidant parameter in a cohort of multiple sclerosis patients
Brain and Behavior
biomarker
multiple sclerosis
oxidative stress
total radical trapping parameter assay
title Plasma antioxidant potential measured by total radical trapping antioxidant parameter in a cohort of multiple sclerosis patients
title_full Plasma antioxidant potential measured by total radical trapping antioxidant parameter in a cohort of multiple sclerosis patients
title_fullStr Plasma antioxidant potential measured by total radical trapping antioxidant parameter in a cohort of multiple sclerosis patients
title_full_unstemmed Plasma antioxidant potential measured by total radical trapping antioxidant parameter in a cohort of multiple sclerosis patients
title_short Plasma antioxidant potential measured by total radical trapping antioxidant parameter in a cohort of multiple sclerosis patients
title_sort plasma antioxidant potential measured by total radical trapping antioxidant parameter in a cohort of multiple sclerosis patients
topic biomarker
multiple sclerosis
oxidative stress
total radical trapping parameter assay
url https://doi.org/10.1002/brb3.3377
work_keys_str_mv AT margekartau plasmaantioxidantpotentialmeasuredbytotalradicaltrappingantioxidantparameterinacohortofmultiplesclerosispatients
AT joonaskartau plasmaantioxidantpotentialmeasuredbytotalradicaltrappingantioxidantparameterinacohortofmultiplesclerosispatients
AT marjattapohja plasmaantioxidantpotentialmeasuredbytotalradicaltrappingantioxidantparameterinacohortofmultiplesclerosispatients
AT auliverkkoniemiahola plasmaantioxidantpotentialmeasuredbytotalradicaltrappingantioxidantparameterinacohortofmultiplesclerosispatients